When heart patients are diagnosed with severe AS, how quickly do they need to undergo TAVR? That was the focus of a new analysis published in Open Heart.
Accessing cardiology data for research or population health initiatives is still quite difficult in Europe. Could this new project help reverse that trend?
The DurAVR transcatheter heart valve, developed by Minnesota-based Anteris Technologies, was designed to move and perform like a healthy, pre-disease native aortic valve.
The new analysis, published in JAMA, suggests that CT results can help identify medium- and high-risk patients who may need to be considered for statin therapy or other preventive treatments.
Daniel Cantillon, MD, explained why the positive performance of Abbott's Aveir dual-chamber leadless pacemaker could lead to considerable improvements in patient care.
Results from a pivotal clinical trial presented as a late-breaker at Heart Rhythm 2023 indicate that a new leadless pacemaker technology can deliver cardiac resynchronization therapy in patients who were not able to be treated with conventional CRT and epicardial leads.
The use of left bundle branch area pacing (LBBAP) is growing in electrophysiology implanted devices. Two late-breaking studies at Heart Rhythm 2023 highlight the success of LBBAP as an alternative to the standard of care using biventricular pacing.
The new drug, asundexian, is currently the subject of two multicenter Phase III studies—the OCEANIC-AF trial and OCEANIC-STROKE trial—focused on its safety and efficacy.
“These and other data support that young adults do as well as a more traditional patient population when looking at arrhythmia-free survival,” researchers wrote.
